May 31, 2022
Life Sciences
  • British drugmaker GSK PLC will buy vaccine manufacturer Affinivax Inc. for up to $3.3 billion, giving it access to promising experimental vaccine technology that targets two dozen common diseases. A GSK executive said Affinivax’s technology could broaden immunization against pneumococcal diseases, which are a major cause of death among children and older people in low-income countries. (Articles here, here, and here)